Looking At M&A History, What Metrics Suggest That Pfizer Has Been Conservative While Engineering Allergan Deal?

+3.09%
Upside
27.75
Market
28.61
Trefis
PFE: Pfizer logo
PFE
Pfizer

Pfier & Allergan Merger Deal

  • Synergies announced as % of combined sales < healthcare sector median
  • Allergan’s fair share of synergies post merger ~  healthcare sector median

 

Pfizer_Question2_Merger

Relevant Articles
  1. Should You Pick Pfizer Stock At $30 After A 30% Fall In A Year?
  2. Should You Pick Pfizer Stock At $30?
  3. Down 25% In A Year Will Pfizer Stock Rebound To Its Pre-Inflation Shock Level?
  4. Will Pfizer Stock See Higher Levels Post Q1 Earnings?
  5. Is Pfizer Stock Undervalued At $40?
  6. This Logistics Company Appears To Be A Better Pick Over Pfizer Stock

Source for Healthcare sector data: How Successful M&A Deals Split the Synergies (complied for M&A activities between 2000 and 2011)

Have more questions about Pfizer? See the links below.

Notes:

1) The purpose of these analyses is to help readers focus on a few important things. We hope such lean communication sparks thinking, and encourages readers to comment and ask questions on the comment section, or email content@trefis.com
2) Figures mentioned are approximate values to help our readers remember the key concepts more intuitively. For precise figures, please refer to our complete analysis for Pfizer

See More at Trefis | View Interactive Institutional Research (Powered by Trefis)

Get Trefis Technology